Loading...
01/11 01:47
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals significant financial challenges, including a sharp revenue decline and increased net losses. Despite having substantial cash reserves, the anticipated high cash burn for 2025 raises concerns. The Q&A section highlights management's lack of clarity on timelines and specifics, which may further unsettle investors. Given these factors and the mid-sized market cap, a negative stock price reaction is likely over the next two weeks.
Revenue $1 million for the full year ended December 31, 2024, down from $4 million in 2023, primarily due to the absence of revenue from the development candidate licensed to Loyal in 2023.
Research and Development Expenses $66.6 million for Q4 2024 and $240.2 million for the full year, compared to $45.6 million and $168.5 million in 2023, reflecting higher personnel costs and increased development activities.
General and Administrative Expenses $28.2 million for Q4 2024 and $99.7 million for the full year, compared to $17.1 million and $58.1 million in 2023, driven by increased personnel costs and commercial planning activities.
Net Loss $80.6 million for Q4 2024, compared to $60.1 million in Q4 2023; for the full year, net loss was $298.4 million, up from $214.5 million in 2023, attributed to increased R&D and G&A expenses.
Cash and Investments Approximately $1.4 billion at the end of 2024, expected to fund operations into 2029.
NDA Acceptance for Paltusotine: The FDA accepted the NDA for paltusotine for the treatment and long-term maintenance therapy of acromegaly, with a PDUFA date set for September 25, 2025.
Paltusotine Launch Preparation: Crinetics is preparing for the anticipated launch of paltusotine by building out its commercial and medical affairs teams.
Atumelnant Clinical Progress: Atumelnant showed significant clinical improvements in a Phase II study for congenital adrenal hyperplasia (CAH) and is progressing towards late-stage studies.
New Drug Candidate 9682: Crinetics plans to submit 4 INDs in 2025, including for 9682, a novel nonpeptide drug conjugate.
European Market Expansion: Crinetics is expanding into Europe with a hub in Zug, Switzerland, and plans to file for EMA approval for acromegaly.
Commercial Infrastructure Development: The company is building a best-in-class commercial and medical affairs organization to support the launch of paltusotine.
Increased R&D Spending: Research and development expenses increased to $240.2 million for the full year 2024, reflecting expanded pipeline activities.
Transition to Commercial Stage: Crinetics is transitioning into a commercial stage company with the hiring of Isabel Kalofonos as Chief Commercial Officer.
Focus on Endocrine Innovation: The company aims to leverage its infrastructure to evolve into a fully integrated global pharmaceutical company.
Regulatory Risks: The company is preparing for the FDA's review of its NDA for paltusotine, with a PDUFA date set for September 25, 2025. Any delays or negative outcomes from this review could impact the company's plans.
Market Access Challenges: Crinetics is working to ensure access to paltusotine, which involves navigating the standard formulary inclusion process with U.S. payers. There is uncertainty regarding the speed and extent of coverage post-launch.
Financial Risks: The company anticipates a cash burn of $340 million to $380 million in 2025, reflecting increased R&D and SG&A expenses as they initiate four late-stage trials. This raises concerns about financial sustainability.
Supply Chain Challenges: As the company expands its clinical trials and commercial infrastructure, it may face supply chain challenges related to the production and distribution of its drug candidates.
Competitive Pressures: Crinetics operates in a competitive market for endocrine therapies, and the success of paltusotine and atumelnant will depend on their ability to differentiate from existing treatments and capture market share.
Clinical Development Risks: There are inherent risks in clinical trials, including potential adverse events, regulatory scrutiny, and the need for additional studies based on safety monitoring outcomes.
NDA Acceptance: The FDA accepted the NDA for paltusotine for the treatment of acromegaly, with a PDUFA date set for September 25, 2025.
Commercial Infrastructure Build-Out: Crinetics is completing the build-out of its commercial and medical affairs teams in preparation for the anticipated launch of paltusotine.
Regional Growth Strategy: The company is pursuing a stepwise regional growth strategy in Europe, with plans to file for EMA approval for acromegaly shortly.
Clinical Trials: Crinetics is activating clinical trial sites for the Phase III trial of paltusotine in carcinoid syndrome, expecting the first patient to enroll in Q2 2025.
Pipeline Development: The company plans to submit 4 INDs in 2025, including for 9682, a novel nonpeptide drug conjugate.
2025 Revenue Expectations: Crinetics anticipates a cash burn of between $340 million and $380 million in 2025 due to the initiation of 4 late-stage trials.
Financial Position: The company ended 2024 with approximately $1.4 billion in cash and investments, expected to fund operations into 2029.
R&D and SG&A Expenses: R&D spending is expected to grow in 2025 as trials ramp up, with SG&A also increasing due to commercial infrastructure build-out.
Cash and Investments: Crinetics ended 2024 with approximately $1.4 billion in cash and investments, which is expected to fund their operating plan into 2029.
Net Loss: The net loss for the year ended December 31, 2024, was $298.4 million.
Anticipated Cash Burn: For 2025, Crinetics anticipates a cash burn between $340 million and $380 million.
R&D Expenses: Research and development expenses were $240.2 million for the full year ended December 31, 2024.
G&A Expenses: General and administrative expenses were $99.7 million for the full year ended December 31, 2024.
The earnings call highlights strong product development and market strategy, especially with the PALSONIFY launch and its appeal to both patients and prescribers. The Q&A section indicates effective execution and positive reception, despite minor uncertainties in payer approval timing. Financial guidance shows controlled cash usage, and the company is well-capitalized. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
The earnings call reveals a mix of positive and cautious elements. While the CRENESSITY launch and positive payer feedback are promising, management's reluctance to comment on consensus numbers and pricing, along with limited updates on liver toxicity and distribution, indicate uncertainty. The market cap suggests moderate sensitivity to news, warranting a neutral prediction.
The earnings call presents a mixed picture: strong year-over-year revenue growth and a decrease in net loss are positive, but lack of current revenue and a net loss remain concerns. The Q&A section reveals uncertainty in regulatory timelines and data disclosures, which can dampen investor confidence. Although there's optimism about paltusotine's market potential and strategic preparations, the absence of immediate revenue and regulatory risks balance out the positives. Given the mid-cap status of Crinetics, the stock is likely to experience a neutral movement in the short term.
The earnings call reveals significant financial challenges, including a sharp revenue decline and increased net losses. Despite having substantial cash reserves, the anticipated high cash burn for 2025 raises concerns. The Q&A section highlights management's lack of clarity on timelines and specifics, which may further unsettle investors. Given these factors and the mid-sized market cap, a negative stock price reaction is likely over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
